anti b7 h3 antibody  (R&D Systems)

Journal: Kidney International Reports

Article Title: Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy

doi: 10.1016/j.ekir.2026.106365

Figure Lengend Snippet: Reconstitution of B-cells over time. To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), CD38 (BV711), CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech). The stained cells were then analyzed using multicolor flow cytometry (BD FACS Lyric). The subsets of gated CD19 + cells were identified based on surface marker expression as follows: naïve (CD19+CD27-IgD+), nonswitched memory (CD19+CD27+IgD+), switched memory (CD19+CD27+IgD-), and double negative (CD19+CD27-IgD-); and within the CD19+CD38++ population, we distinguished transitional cells (CD19+CD38++CD27-IgD+), plasmablasts (CD19+CD38++CD27+IgD-), and double-negative CD38 + cells (CD19+CD38++CD27-IgD-). B-cell subsets were expressed as a percentage of the total lymphocyte count. (a) B-cell subpopulations were assessed in 39 patients at baseline and in 36 patients at 3 (M3), 6 (M6), 9 (M9), 12 (M12), and 18 (M18) months following the first rituximab infusion. The 3 patients who did not receive treatment were excluded from the follow-up. Complete depletion of B-cells was observed in all patients at M3 post-rituximab for all B-cell subpopulations. CD19 + cells reappeared 6 months after rituximab infusion. Naive cells re-emerged the most among B-cells, followed by CD38 + cells, transitional cells and finally memory cells. Data are shown as mean values (dots). (b–k) B-cell subpopulations at baseline and at subsequent time points were compared between relapsing patients ( n = 8) and nonrelapsing patients ( n = 19); the 2 patients who received additional anti-CD20 infusions were excluded from subsequent analyses. Data are shown as medians and interquartile range (IQR). P -values were calculated by comparing the median values of each cell subpopulation between relapsing and nonrelapsing patients using a nonparametric, unpaired Mann–Whitney U test.

Article Snippet: To characterize B-cell subsets, peripheral blood mononuclear cells were stained with fluorochrome-conjugated monoclonal antibodies (BD Biosciences) directed against the following antigens: CD45 (V500-C), CD3 (APC), CD19 (APC-H7), CD27 (BV421), IgD (PE), CD38 (BV711), CD4 (BV605), and CD8 (PE), as well as 7-AAD (Miltenyi Biotech).

Techniques: Staining, Bioprocessing, Flow Cytometry, Marker, Expressing, MANN-WHITNEY

Journal: bioRxiv

Article Title: Transcription Factor–Mediated Reprogramming of Cancer-Associated Fibroblasts Reveals Targetable Vulnerabilities in Solid Tumors

doi: 10.64898/2026.04.15.718753

Figure Lengend Snippet: A. Immunocytochemistry (ICC) analysis demonstrates strong B7-H3 (CD276) expression on both PC-3 cancer cells and pCAFs, visualized by red fluorescence. B. In 2D co-culture assays, anti-B7-H3 CAR T cells exhibit antigen-specific cytotoxicity against PC-3 cells, with killing efficiency increasing across graded effector-to-target (E:T) ratios.

Article Snippet: Primary human anti–B7-H3 antibody (AF1027, R&D Systems) was diluted in cold staining buffer (0.5 μg/μL; 2 μL per 100 μL reaction volume) and applied to cells for 20–30 min at 4 °C.

Techniques: Immunocytochemistry, Expressing, Fluorescence, Co-Culture Assay

Journal: bioRxiv

Article Title: Transcription Factor–Mediated Reprogramming of Cancer-Associated Fibroblasts Reveals Targetable Vulnerabilities in Solid Tumors

doi: 10.64898/2026.04.15.718753

Figure Lengend Snippet: Stromal Effects on CAR T-Cell Activity in 3D-Bioprinted PC-3 Spheroids. A. Representative images of stromal populations influencing anti-B7-H3 CAR T-cell killing function . B. PC-3 spheroid with pCAF/rpNFs interaction with CAR-T cells monitored by IncuCyte imaging system. C. The killing effects of B7-H3 CAR T cells on PC-3 cells in day 5 compared to day 1. D . Imaging of live cells at different time.

Article Snippet: Primary human anti–B7-H3 antibody (AF1027, R&D Systems) was diluted in cold staining buffer (0.5 μg/μL; 2 μL per 100 μL reaction volume) and applied to cells for 20–30 min at 4 °C.

Techniques: Activity Assay, Imaging